Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

Individuals with STXBP1 mutations can develop treatment-resistant seizures, severe developmental delay and intellectual disabilities, motor abnormalities, and sudden unexpected death in epilepsy.

In the field of myelodysplastic syndromes (MDS), there are a number of investigational studies designed with the hope of ...

Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. Fast Track Designation for LP-184 (STAR-001 ...

In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...

Out-of-pocket costs for branded drugs to treat multiple sclerosis (MS), Alzheimer's, and Parkinson's disease rose from 2012 ...

HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration: Shanghai Tuesday, November 5, 2024, 09:00 Hrs [IST] HuidaGene Therapeutic ...

A: The majority of inquiries are related to regulatory issues, such as the drug review process, and are classified as follows: investigational new drugs (16%), new drugs (13%), generic drugs (17% ...